Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 1998 March;50(1) > Minerva Urologica e Nefrologica 1998 March;50(1):113-4

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  XIV CONGRESS OF THE SOCIETA' ITALIANA DI NEFROLOGIA SEZIONE PIEMONTE-VALLE D'AOSTA
(Ivrea, October 5, 1996)
 

Minerva Urologica e Nefrologica 1998 March;50(1):113-4

Copyright © 1998 EDIZIONI MINERVA MEDICA

language: Italian

Magnesium hydroxide in idiopathic calcium nephrolithiasis

Vagelli G., Calabrese G., Pratesi G., Mazzotta A., Gonella M.

USL n. 21 - Casale Monferrato (Alessandria), Servizio di Nefrologia e Dialisi


PDF


Background. While in vitro the protective effect of magnesium on calcium oxalate crystallization is well known, its clinical relevance in calcium nephrolithiasis is still debated. Therefore, the clinical and metabolic effects of magnesium hydroxide therapy were evaluated in calcium stone formers.
Methods. Nine patients (7 M, 2 F), selected for a low urinary magnesium excretion (uMg 56±12 mg/day), were given Mg hydroxide (500 mg/day), with clinical and metabolic controls at 3, 12 and 18 months.
Results. Urinary Mg/u Creat increased throughout the study; uOx/uCreat decreased significantly; uCa/uCreat increased but not significantly. The stone recurrence rate decreased from 0.75 to 0.11 stones/year/patient, thoughout the study period. The decrease of uOx is considered a more important risk factor in calcium stone patients than a similar uCa change; it may be due to a reduced intestinal Ox absorption, for the formation of insoluble and not absorbed Mg oxalate.
Conclusion. In conclusion, Mg hydroxide therapy was encouraging in patients with calcium nephrolithiasis and low uMg; nevertheless a longer period of treatment is needed to confirm these data.

top of page